The Voltron team has extensive experience driving innovative commercialization initiatives.
They have collectively filed more than 70 Investigational New Drug (IND) applications, executed 130+ clinical trials, authored more than 500 scientific papers, and contributed to 15 FDA product approvals and 16 product launches.
Leadership Team
Patrick Gallagher, CFA
Chief Executive Officer
Co-founder of Voltron Therapeutics. 30+ years of healthcare and capital markets experience.
Pat Gallagher co-founded Voltron therapeutics in 2017 and serves as its CEO and as a director. Under his direction, Voltron has built a senior team with extensive experience in manufacturing, development, clinical operations, regulatory, commercial, and basic research.
Paul Korner, MD, MBA
Director
25+ years of experience. 50+ clinical trials leading to marketing authorization/approvals of 11 products.
Paul Korner is a physician executive with over 25 years of biopharma experience, with 15 years at Senior/C-level positions with private & public companies. He has experience across novel pathways across, development phases and has been responsible for multiple INDs/CTAs and more than 50 clinical trials leading to marketing authorization/approvals of 11 products including VYONDYS 53® (golodirsen), NOCDURNA® (desmopressin), PREPOPIK® (sodium picosulfate), EUFLEXXA® (1% sodium hyaluronate), and YAZ® (EE/drospiranone).
Simon Pedder, PhD
Director, Clinical Strategy
30+ years in drug development and commercialization. Senior leadership of oncology and infectious disease franchises.
Dr. Pedder has over 30 years in drug development and commercialization, including as Global Vice President of Oncology Pharma Business and Executive Officer at Hoffmann-LaRoche. Simon was also the Chief Executive Officer of Nirogy.
Jeffrey A. Gelfand M.D
R&D, Strategy
30+ years in drug development and commercialization. Senior leadership of oncology and infectious disease franchises.
Dr. Gelfand is a Physician in the Infectious Diseases Division at Massachusetts General Hospital (MGH) and Professor of Medicine at Harvard Medical School. He is a Senior Scientist in the MGH Vaccine and Immunotherapy Center. He is also Adjunct Faculty in the Wellman Center for Photomedicine at MGH.
Joseph T. Schepers
Investor Relations and Business Development
25+ years of healthcare experience. Investor Relations, Communications, and Business Development with oncology and infectious disease expertise.
Joseph T. Schepers has more than 25 years of experience in Investor Relations, Corporate Communications and Business Development in biotechnology, pharmaceuticals, specialty pharmaceuticals, medical devices, consumer health and vision care.
Dr. Mark C Poznansky
R&D, Pre-Clinical Development
Scientific co-founder of Voltron. Director of the Vaccine and Immunotherapy Center (VIC), Physician at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School.
Director of the Vaccine and Immunotherapy Center (VIC), Physician at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School.
Matthew Duffy
Strategy, Director
35+ years of healthcare-related business and investment banking expertise.
Mr. Duffy has served as President (through 2024) and Director (current) of Voltron Therapeutics since 2019, and Director of Algorithm Sciences (2010) and AerWave Medical (2020). He was also President and Director of PD Theranostics from 2019 until the merger with Ovation.io in 2024.
Ishan Capila, PhD
CMC Regulatory Strategy
30+ years biotechnology research experience with expertise in early-stage drug development through regulatory filings in oncology and infectious diseases.
Dr. Capila is a scientific leader and biotech executive with over 30 years of research experience, and over 20 years of industry experience spanning novel drug discovery and development, complex generic drugs, and biosimilars.
Scientific Team
Dr. Mark C Poznansky
Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific advisory board member to help advise on the early clinical research and implementation of testing in the hospital setting and to help gather additional academic and clinical KOLs to serve on the SAB.
Jeffrey Gelfand, MD
Dr. Jeffrey A. Gelfand is an infectious disease specialist in Boston, Massachusetts. He received his medical degree from Tufts University School of Medicine and has been in practice for more than 20 years. Dr. Gelfand’s specializes in infectious disease. He is also a Clinical Professor of Medicine, where he has developed a novel approach for targeting (tumor) antigens whose sequence may not be known or structure even identified.
Development and Operations Advisory Team
Clinical Operations – 30+ years of experience. Responsibilities include R&D strategy, overseeing clinical trials, and ensuring regulatory compliance. Responsible for selecting and managing 3rd party vendors that support non-clinical and clinical development.
CMC – 25+ years of experience. Extensive technical experience in engineering, process development, quality assurance, and the manufacturing of biologics, vaccines, cyto-toxic oncology, and other sterile products. He has been involved in the commercialization of an array of biologics and vaccines throughout his career.